The objective was to measure the impact of exposure to coxibs and non-steroidal antiinflammatory drugs (NSAID) on morbidity and mortality in older patients with acute myocardial infarction (AMI). A nested case-control study was carried out using an exhaustive population-based cohort of patients aged 66 years and older living in Quebec (Canada) who survived a hospitalization for AMI (ICD-9 410) between 1999 and 2002. The main variables were all-cause and cardiovascular (CV) death, subsequent hospital admission for AMI, and a composite end-point including recurrent AMI or CV death. Conditional logistic regressions were used to estimate the risk of mortality and morbidity. A total of 19,823 patients aged 66 years and older survived hospitalization for AMI in the province of Quebec between 1999 and 2002. After controlling for covariables, the risk of subsequent AMI and the risk of composite end-point were increased by the use of rofecoxib. The risk of subsequent AMI was particularly high for new rofecoxib users (HR 2.47, 95% CI 1.57-3.89). No increased risk was observed for celecoxib users. No increased risk of CV death was observed for patients exposed to coxibs or NSAIDs. Patients newly exposed to NSAIDs were at an increased risk of death (HR 2.22, 95% CI 1.30-3.77) and of composite end-point (HR 2.28, 95% CI 1.35-3.84). Users of rofecoxib and NSAIDs, but not celecoxib, were at an increased risk of recurrent AMI and of composite end-point. Surprisingly, no increased risk of CV death was observed. Further studies are needed to better understand these apparently contradictory results.
Cyclooxygenase-2, non-steroidal antiinflammatory drugs, cardiovascular mortality, acute myocardial infarction.
Alain Vanasse, Department of Family Medicine, Faculty of Medicine, Université de Sherbrooke 3001 12th Avenue North, Sherbrooke (Quebec) J1H 5N4, Canada. E-mail: Alain.Vanasse@USherbrooke.ca
Share this Article
Related Content In Cardiovascular Disease
ST-elevation Myocardial Infarction and Multivessel Coronary Artery Disease – A Critical Review of Current Practice, Evidence and Meta-analyses
Heart International. 2020;14(2):80-5 DOI: https://doi.org/10.17925/HI.2020.14.2.80
Reperfusion of infarct-related artery (IRA) in acute ST-elevation myocardial infarction (STEMI) is the procedure with the most clinical benefit in interventional cardiology. However, in around 50% of patients presenting with STEMI, other significant lesions are present, a finding which is associated to a worse prognosis.1,2 Most physicians performing primary percutaneous coronary intervention (PCI) have been trained […]
The Role of Transoesophageal Echocardiography in Surgical Removal of a Mediastinal Tumour
Heart International. 2020;14(2):118-20 DOI: https://doi.org/10.17925/HI.2020.14.2.118
Perioperative management of a mediastinal tumour is an anaesthetic challenge. Echocardiography is not considered as a primary diagnostic modality in the evaluation of a mediastinal mass; however, it can provide valuable information in patients with clinical and diagnostic evidence of cardiac compression or encroachment. Judicious interpretation of perioperative transthoracic or transoesophageal echocardiographic images may be […]
Ratio of Serum Aspartate to Alanine Aminotransferase as a Marker of Isolated Coronary Artery Ectasia and its Severity
Heart International. 2020;14(1):43–8 DOI: https://doi.org/10.17925/HI.2020.14.1.43
The exact aetiology of coronary artery ectasia (CAE) has yet to be fully elucidated; however, some underlying aetiologies such as atherosclerosis and microvascular abnormalities in coronary arteries have been proposed.1,2 Over the past few years, several inflammatory markers have been introduced as indicators of CAE and its severity. There is an association between the development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!